MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. ; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Follow-Up Questions
Mediwound Ltd 'in CEO'su kimdir?
Mr. Ofer Gonen 2003 'den beri şirketle birlikte olan Mediwound Ltd 'in Chief Executive Officer 'ıdır.
MDWD hissesinin fiyat performansı nasıl?
MDWD 'in mevcut fiyatı $17.22 'dir, son işlem günde 0.17% decreased etti.
Mediwound Ltd için ana iş temaları veya sektörler nelerdir?
Mediwound Ltd Pharmaceuticals endüstrisine ait ve sektör Health Care 'dir
Mediwound Ltd 'in piyasa değerlemesi nedir?
Mediwound Ltd 'in mevcut piyasa değerlemesi $187.3M 'dir
Mediwound Ltd al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 8 analist Mediwound Ltd için analist derecelendirmeleri gerçekleştirdi, bunlar 3 güçlü al, 8 al, 1 tut, 0 sat ve 3 güçlü sat içermektedir
